Wound Care Biologics Market

Executive Summary

Wound Care Biologics Market was valued at US $1.97 billion in 2021 and is projected to grow at 9.28% CAGR over the forecast period to reach US $3.35 billion by 2027. Wound Care Biologics Market represented US $0.32 billion opportunity over 2019-2021 and estimated to create US $1.38 billion opportunity in 2027 over 2021.

Wound Care Biologics from Consainsights analyses the Wound Care Biologics Market in the Life Sciences industry over the forecast period to 2027.

Wound Care Biologics research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Wound Care Biologics segmentation includes Product, Wound Type, End User, Region and Geography.

Based on the Product, the Wound Care Biologics analysis covers Biological Skin Substitutes, Topical Agents.

In Product segment, Biological Skin Substitutes segment has highest cagr growth of 8.21%.

Based on the Wound Type, the Wound Care Biologics analysis covers Ulcers, Surgical & Traumatic Wounds, Burns.

In Wound Type segment, Ulcers segment has highest cagr growth of 8.21%.

Based on the End User, the Wound Care Biologics analysis covers Hospitals, Ambulatory Surgical Centers, Burn Centers and Wound Clinics.

In End User segment, Hospitals segment has highest cagr growth of 8.21%.

Based on the Region, the Wound Care Biologics analysis covers North America, Europe, Asia Pacific, Rest of the World.

In Region segment, North America segment has highest cagr growth of 8.21%.

Based on the region, the Wound Care Biologics analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Smith & Nephew, Mölnlycke Health Care AB (Investor AB), Integra Lifesciences, Wright Medical, Mimedx Group, Vericel, Anika Therapeutics, Osiris Therapeutics, Organogenesis, Kerecis, Solsys Medical, Acell, Marine Polymer Technologies and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product

Introduction

In 2021, Topical Agents segment has the highest revenue of US $1.09 billion and is expected to grow at CAGR of 8.21% by 2027 Biological Skin Substitutes segment has highest cagr growth of 8.21%.

Biological Skin Substitutes

Biological Skin Substitutes segment was valued at US $0.73 billion in 2019 and is projected to grow at 8.21% CAGR over the forecast period to reach US $1.49 billion by 2027. Biological Skin Substitutes segment represented US $0.14 billion opportunity over 2019-2021 and estimated to create US $0.62 billion opportunity in 2027 over 2021.

Topical Agents

Topical Agents segment was valued at US $0.91 billion in 2019 and is projected to grow at 8.21% CAGR over the forecast period to reach US $1.86 billion by 2027. Topical Agents segment represented US $0.18 billion opportunity over 2019-2021 and estimated to create US $0.77 billion opportunity in 2027 over 2021.

Wound Type

Introduction

In 2021, Ulcers segment has the highest revenue of US $1.06 billion and is expected to grow at CAGR of 8.21% by 2027 Ulcers segment has highest cagr growth of 8.21%.

Ulcers

Ulcers segment was valued at US $0.89 billion in 2019 and is projected to grow at 8.21% CAGR over the forecast period to reach US $1.80 billion by 2027. Ulcers segment represented US $0.17 billion opportunity over 2019-2021 and estimated to create US $0.74 billion opportunity in 2027 over 2021.

Surgical & Traumatic Wounds

Surgical & Traumatic Wounds segment was valued at US $0.68 billion in 2019 and is projected to grow at 8.21% CAGR over the forecast period to reach US $1.39 billion by 2027. Surgical & Traumatic Wounds segment represented US $0.13 billion opportunity over 2019-2021 and estimated to create US $0.57 billion opportunity in 2027 over 2021.

Burns

Burns segment was valued at US $0.08 billion in 2019 and is projected to grow at 8.21% CAGR over the forecast period to reach US $0.16 billion by 2027. Burns segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.07 billion opportunity in 2027 over 2021.

End User

Introduction

In 2021, Hospitals segment has the highest revenue of US $1.08 billion and is expected to grow at CAGR of 8.21% by 2027 Hospitals segment has highest cagr growth of 8.21%.

Hospitals

Hospitals segment was valued at US $0.90 billion in 2019 and is projected to grow at 8.21% CAGR over the forecast period to reach US $1.83 billion by 2027. Hospitals segment represented US $0.17 billion opportunity over 2019-2021 and estimated to create US $0.76 billion opportunity in 2027 over 2021.

Ambulatory Surgical Centers

Ambulatory Surgical Centers segment was valued at US $0.42 billion in 2019 and is projected to grow at 8.21% CAGR over the forecast period to reach US $0.86 billion by 2027. Ambulatory Surgical Centers segment represented US $0.08 billion opportunity over 2019-2021 and estimated to create US $0.36 billion opportunity in 2027 over 2021.

Burn Centers and Wound Clinics

Burn Centers and Wound Clinics segment was valued at US $0.32 billion in 2019 and is projected to grow at 8.21% CAGR over the forecast period to reach US $0.66 billion by 2027. Burn Centers and Wound Clinics segment represented US $0.06 billion opportunity over 2019-2021 and estimated to create US $0.27 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, North America segment has the highest revenue of US $0.97 billion and is expected to grow at CAGR of 8.21% by 2027 North America segment has highest cagr growth of 8.21%.

North America

North America segment was valued at US $0.82 billion in 2019 and is projected to grow at 8.21% CAGR over the forecast period to reach US $1.66 billion by 2027. North America segment represented US $0.16 billion opportunity over 2019-2021 and estimated to create US $0.69 billion opportunity in 2027 over 2021.

Europe

Europe segment was valued at US $0.38 billion in 2019 and is projected to grow at 8.21% CAGR over the forecast period to reach US $0.76 billion by 2027. Europe segment represented US $0.07 billion opportunity over 2019-2021 and estimated to create US $0.32 billion opportunity in 2027 over 2021.

Asia Pacific

Asia Pacific segment was valued at US $0.34 billion in 2019 and is projected to grow at 8.21% CAGR over the forecast period to reach US $0.69 billion by 2027. Asia Pacific segment represented US $0.07 billion opportunity over 2019-2021 and estimated to create US $0.28 billion opportunity in 2027 over 2021.

Rest of the World

Rest of the World segment was valued at US $0.12 billion in 2019 and is projected to grow at 8.21% CAGR over the forecast period to reach US $0.24 billion by 2027. Rest of the World segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.10 billion opportunity in 2027 over 2021.